{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-069935","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2023-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.306874+00:00","generated_at":"2026-06-18T04:06:09.567359+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veru refocuses on sabizabulin for COVID/influenza; terminates prostate cancer trial, pauses two assets","bullets":["Terminating Phase 3 VERACITY trial of sabizabulin in prostate cancer; pausing Phase 2 Veru-100 and zuclomiphene development.","Plans Phase 3 confirmatory study of sabizabulin for hospitalized moderate/severe COVID-19 patients at high risk for ARDS.","Plans Phase 3 study of sabizabulin for hospitalized influenza patients at high risk for ARDS.","Updated Phase 3 ENABLAR-2 study of enobosarm + abemaciclib for second-line metastatic breast cancer; rolling ARTEST into it pending FDA/Lilly approval.","Cash conservation measures including personnel reduction; prior FDA denial of EUA for sabizabulin on March 2, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-069935","json":"https://secwatch.observer/filing/0001193125-23-069935.json","markdown":"https://secwatch.observer/filing/0001193125-23-069935.md","text":"https://secwatch.observer/filing/0001193125-23-069935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000119312523069935/0001193125-23-069935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000119312523069935/d254341d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T04:06:09.567359+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}